home / stock / aneb / aneb news

ANEB News and Press, Anebulo Pharmaceuticals Inc. From 05/11/22

Stock Information
Company Name: Anebulo Pharmaceuticals Inc.
Stock Symbol: ANEB
Market: NASDAQ
Website: anebulo.com
Menu
ANEB ANEB Quote ANEB Short ANEB News ANEB Articles ANEB Message Board
Get ANEB Alerts

News, Short Squeeze, Breakout and More Instantly...
ANEB - Anebulo Pharmaceuticals GAAP EPS of -$0.08 misses by $0.03

Anebulo Pharmaceuticals press release (NASDAQ:ANEB): Q3 GAAP EPS of -$0.08 misses by $0.03. Cash and cash equivalents were $16.5 million as of March 31, 2022. For further details see: Anebulo Pharmaceuticals GAAP EPS of -$0.08 misses by $0.03

ANEB - Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the “Company” or “Anebulo”), today announced financial result...

ANEB - Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND Submission

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the “Company” or “Anebulo”), today announced t...

ANEB - Anebulo Pharmaceuticals GAAP EPS of -$0.05

Anebulo Pharmaceuticals press release (NASDAQ:ANEB): Q2 GAAP EPS of -$0.05. Cash and cash equivalents were $18M as of December 31, 2021 For further details see: Anebulo Pharmaceuticals GAAP EPS of -$0.05

ANEB - Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2022 Financial Results and Recent Updates

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the “Company” or “Anebulo”), today announced financial result...

ANEB - Anebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announces that management will present a company overview at the H.C. Wainwright BioConne...

ANEB - Anebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public Relations

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announced today that it has appointed Scott L. Anderson as Head of Investor Relations and...
ANEB - Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, has named Simon Allen as Chief Executive Officer and a member of the company’s Boa...

ANEB - Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication

Affirms expectations for initial topline results in 1H 2022 Recent FDA pre-IND meeting provides valuable guidance on U.S. regulatory path; company expects to submit IND in 1Q 2022 Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical co...

ANEB - Anebulo Pharmaceuticals EPS beats by $0.04

Anebulo Pharmaceuticals (NASDAQ:ANEB): FQ1 GAAP EPS of -$0.07 beats by $0.04. Cash of $19.20M Press Release For further details see: Anebulo Pharmaceuticals EPS beats by $0.04

Previous 10 Next 10